TTR and amyloidosis: In 2018, DLin-MC3-DMA (MC3) LNPs, a type of ionizable lipid, were approved by the Food and Drug Administration (FDA) for siRNA delivery to hepatocytes for treating transthyretin (TTR)-induced amyloidosis [206].